There is a multi-site trial kicking off for MT-3921 around the US (phase 1 safety) and when I looked I found

MT-3921 is a novel investigational drug developed jointly with Osaka University that will contribute to expanding Mitsubishi Tanabe Pharma?s pipeline in neurological disorders, which is one of the focus areas for the Company.
RGMa (repulsive guidance molecule A) was discovered in the 1990?s; however, until recently its role has not been fully understood. Current nonclinical research determined that RGMa is associated with inhibition of protection and regeneration of neurons and progression of inflammation. Additionally, it has revealed that RGMa plays a role in neurological diseases (spinal cord injury, stroke, multiple sclerosis etc.).
MT-3921 is a humanized anti-RGMa antibody that has been developed jointly by Mitsubishi Tanabe Pharma and Pr. Yamashita?s research group since 2005, and is based on initial research by Pr. Yamashita. Pre-clinical studies were conducted by his research group and the Company. Previous research was supported by a grant from the Japan Agency for Medical Research and Development (AMED) and showed that MT-3921 improves locomotor function and promotes neuroregeneration in rat and monkey spinal cord injury models.
Spinal cord injury has been a primary treatment target for regenerative medicine in recent years; however, an effective treatment has yet to be identified.
A phaseⅠclinical trial has been underway in healthy adults in Japan. Now, Mitsubishi Tanabe Pharma Development America, Inc. will initiate a phaseⅠclinical trial in patients with spinal cord injury in the US.

There also seems to be a paper that was done on it in 2006.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063787/

Does anyone know anything else about this?
I saw that the initial work was done on acute models, wondering if its relevant to chronic?